Currently, resveratrol is the only known GLUT1 inhibitor in the clinical trials phase for cancers such as multiple myeloma, gastrointestinal tumors, follicular lymphoma and breast cancer (Table 2). This evidence concerns the gene SLC2A1 and breast cancer.